Capps had planned a series of “very carefully controlled” experiments. But now, with nothing else to try, he administered the serum to all as it arrived—it was in short supply. It seemed to work. Two hundred and thirty-four men suffering from pneumonia received the serum; only 16.7 percent died, while more than half of those who did not receive it died. But it was in short supply.
